Garuda - Garba Rujukan Digital

Literatur Review Trastuzumab Induced Cardiotoxicity (TIC) In Patient With Breast Cancer : Pharmacology Aspect, Mechanism of Cardiotoxicity, Risk Factor and Treatment Strategies Jaya, Nur
Pharmaceutical Journal of Indonesia Vol 5, No 1 (2019)
Publisher : Brawijaya University

Show Abstract | Download Original | Original Source | Check in Google Scholar

Background: Breast cancer (BCA) is the most common cancer in women. Since the last 2 decades, early diagnosis and specific molecular targeted neoadjuvant and adjuvant therapy had been reducing breast cancer mortalities. Unfortunately, the improvement of the survival rate is followed by the emergence of cardiotoxicity effect from cancer therapy that had seen in several cases. This showed that trastuzumab treatment significantly affects the functional and structural characteristics of the heart. The mechanism of trastuzumab-related cardiotoxicity is not fully understood. This review will summarize the pharmacology and mechanism of trastuzumab-induced cardiotoxicity, investigate its risk factors, and consider the appropriate management for the patients.Discussion: Trastuzumab is a monoclonal antibody, that acts as human epidermal growth factor tyrosine kinase HER2 (Erb B2) antagonist, frequently given for breast cancer patients. Trastuzumab is not only expressed through the excessive HER2 in positive breast cancer but can also disrupt the cardiomyocytes growth and selectively inhibit the structure and function of the heart causing dilated cardiomyopathy. Some studies recommended angiotensin-converting enzyme inhibitor (ACEI), enalapril, to prevent the late cardiotoxicity and angiotensin receptors blocker (ARB) and also beta-blocker (BB), candesartan and bisoprolol, to significantly reduce LV dysfunction event, as the management of trastuzumab-induced cardiotoxicity.Conclusion: Delaying trastuzumab administration after previous anthracycline treatment can prevent or reduce the risk/synergy effect of cardiotoxicity. The temporal withdrawal and reinitiation after LV systolic function stabilization, both spontaneously or using heart failure therapy, partially succeed in preventing cardiotoxicity. And, monitoring the troponin release was found as the first and the most sensitive test to detect cardiotoxicity early signs, with a proven impact on cardiac prognosis, particularly for trastuzumab (after the previous anthracycline).Keywords: Trastuzumab-Induced Cardiotoxicity; Pharmacology Aspect, Mechanism of Cardiotoxicity, Risk Factor and Treatment Strategies.

Literatur Review Trastuzumab Induced Cardiotoxicity (TIC) In Patient With Breast Cancer : Pharmacology Aspect, Mechanism of Cardiotoxicity, Risk Factor and Treatment Strategies Jaya, Nur
Pharmaceutical Journal of Indonesia Vol 5, No 1 (2019)
Publisher : Brawijaya University

Show Abstract | Download Original | Original Source | Check in Google Scholar

Background: Breast cancer (BCA) is the most common cancer in women. Since the last 2 decades, early diagnosis and specific molecular targeted neoadjuvant and adjuvant therapy had been reducing breast cancer mortalities. Unfortunately, the improvement of the survival rate is followed by the emergence of cardiotoxicity effect from cancer therapy that had seen in several cases. This showed that trastuzumab treatment significantly affects the functional and structural characteristics of the heart. The mechanism of trastuzumab-related cardiotoxicity is not fully understood. This review will summarize the pharmacology and mechanism of trastuzumab-induced cardiotoxicity, investigate its risk factors, and consider the appropriate management for the patients.Discussion: Trastuzumab is a monoclonal antibody, that acts as human epidermal growth factor tyrosine kinase HER2 (Erb B2) antagonist, frequently given for breast cancer patients. Trastuzumab is not only expressed through the excessive HER2 in positive breast cancer but can also disrupt the cardiomyocytes growth and selectively inhibit the structure and function of the heart causing dilated cardiomyopathy. Some studies recommended angiotensin-converting enzyme inhibitor (ACEI), enalapril, to prevent the late cardiotoxicity and angiotensin receptors blocker (ARB) and also beta-blocker (BB), candesartan and bisoprolol, to significantly reduce LV dysfunction event, as the management of trastuzumab-induced cardiotoxicity.Conclusion: Delaying trastuzumab administration after previous anthracycline treatment can prevent or reduce the risk/synergy effect of cardiotoxicity. The temporal withdrawal and reinitiation after LV systolic function stabilization, both spontaneously or using heart failure therapy, partially succeed in preventing cardiotoxicity. And, monitoring the troponin release was found as the first and the most sensitive test to detect cardiotoxicity early signs, with a proven impact on cardiac prognosis, particularly for trastuzumab (after the previous anthracycline).Keywords: Trastuzumab-Induced Cardiotoxicity; Pharmacology Aspect, Mechanism of Cardiotoxicity, Risk Factor and Treatment Strategies.

Overview of the Use of Oralit and Zinc in Children with Diarrhea at the Community Health Center: Gambaran Penggunaan Oralit dan Zinc Pada Anak Penderita Diare Di Puskesmas Jaya, Nur; Saskia, Ni Nyoman Lisna
Indonesian Journal of Innovation Multidisipliner Research Vol. 1 No. 2 (2023): June
Publisher : Institute of Advanced Knowledge and Science

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.69693/ijim.v1i2.156

Diarrhea is still one of the main problems can cause illness and death, especially in children. Diarrhea is an infectious disease caused by bacteria, virus or other microorganism which is characterized by abnormal frequency of defecation, 3 or more times in 24 hours with a soft feces consistency, the presence or absence of blood or foam in the feces. Giving oralit and zinc can reduce the incidence of diarrhea in children. The aim of this study was to determine the description of the use oralit and zinc in children suffering from diarrhea at the kawatuna Community Health Center during the peroid October 2022-March 2023. Method of this study is retrospective descriptive using secondary data, namely prescription sheets for pediatric patients with diarrhea who received oralit and zinc therapy. The research results showed that the population of diarrhea cases was 125 and the sample used was 96 cases. The highest use of oralit and zinc for treating casess of diarrhea is in October 2022 and the least in March 2023. The age of children most a affected by diarrhea is 1-6 months (50%) and the age least affected by diarrhea is 12-17 years (7,3%).

Overview of the Use of Oralit and Zinc in Children with Diarrhea at the Community Health Center: Gambaran Penggunaan Oralit dan Zinc Pada Anak Penderita Diare Di Puskesmas Jaya, Nur; Saskia, Ni Nyoman Lisna
Indonesian Journal of Innovation Multidisipliner Research Vol. 1 No. 2 (2023): June
Publisher : Institute of Advanced Knowledge and Science

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.69693/ijim.v1i2.156

Diarrhea is still one of the main problems can cause illness and death, especially in children. Diarrhea is an infectious disease caused by bacteria, virus or other microorganism which is characterized by abnormal frequency of defecation, 3 or more times in 24 hours with a soft feces consistency, the presence or absence of blood or foam in the feces. Giving oralit and zinc can reduce the incidence of diarrhea in children. The aim of this study was to determine the description of the use oralit and zinc in children suffering from diarrhea at the kawatuna Community Health Center during the peroid October 2022-March 2023. Method of this study is retrospective descriptive using secondary data, namely prescription sheets for pediatric patients with diarrhea who received oralit and zinc therapy. The research results showed that the population of diarrhea cases was 125 and the sample used was 96 cases. The highest use of oralit and zinc for treating casess of diarrhea is in October 2022 and the least in March 2023. The age of children most a affected by diarrhea is 1-6 months (50%) and the age least affected by diarrhea is 12-17 years (7,3%).

Pengaruh Hemodialisa Terhadap Nilai Hemoglobin dan Kreatinin Pada Pasien Penyakit Ginjal Kronik Di Unit Hemodialisa RSUD Undata Jaya, Nur; Tanjung, Revi Maylina; Khoiriyah, Rani; Muharni, Melvi; Setyawan, Teguh; Permatasari, Defia Indah; Rizal B, Muh.; Adam, Meyzaluna Salsabila
Jurnal Altifani Penelitian dan Pengabdian kepada Masyarakat Vol. 5 No. 6 (2025): November 2025 - Jurnal Altifani Penelitian dan Pengabdian kepada Masyarakat
Publisher : Indonesian Scientific Journal

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.59395/altifani.v5i6.962

Penelitian ini bertujuan untuk mengetahui pengaruh hemodialisa terhadap kadar hemoglobin dan kreatinin pada pasien gagal ginjal kronik di Unit Hemodialisa RSUD Undata. Penelitian ini menggunakan metode kuantitatif dengan desain pre-eksperimental jenis one group pretest-posttest. Sampel sebanyak 88 pasien diambil menggunakan teknik purposive sampling. Data kadar hemoglobin dan kreatinin sebelum dan sesudah hemodialisa dianalisis menggunakan uji Paired Sample T-Test. Hasil penelitian menunjukkan bahwa kadar kreatinin sebelum hemodialisa sebesar 11,464 gr% menurun menjadi 9,211 gr% setelah hemodialisa dengan nilai signifikansi p = 0,00017 (p < 0,05). Sementara itu, kadar hemoglobin meningkat dari 9,440 gr% menjadi 9,939 gr% setelah hemodialisa, dengan nilai p = 0,00053 (p < 0,05). Hasil ini menunjukkan bahwa terdapat perbedaan yang signifikan sebelum dan sesudah hemodialisa. Dapat disimpulkan bahwa hemodialisa memberikan pengaruh yang signifikan terhadap penurunan kadar kreatinin dan peningkatan kadar hemoglobin pada pasien gagal ginjal kronik. Diperlukan pemantauan berkelanjutan terhadap parameter darah lainnya selama terapi hemodialisa untuk mendukung keberhasilan terapi.

Determination of Kinetic and Thermodynamic Parameters of Pb(II) Ion Adsorption Using Dithizone-Immobilized Coal Fly Ash Rizal B., Muh; Mudasir, Mudasir; Siswanta, Dwi; Muharmi, Melvi; Ardina, Vebria; Setyawan, Teguh; Jaya, Nur; Permatasari, Defia Indah; Tanjung, Revi Maylina
Jurnal Kimia Sains dan Aplikasi Vol 29, No 1 (2026): Volume 29 Issue 1 Year 2026
Publisher : Chemistry Department, Faculty of Sciences and Mathematics, Diponegoro University

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.14710/jksa.29.1.1-9

The immobilization of dithizone on the surface of coal fly ash was successfully achieved, as evidenced by Fourier-transform infrared (FT-IR) and X-ray diffraction (XRD) characterization. The dithizone-immobilized coal fly ash (CFA-Dzt) was then used for Pb(II) ion adsorption. The parameters studied included the effects of pH, kinetics, and thermodynamics on Pb(II) ion adsorption using a batch experimental system. The results showed that the optimum pH for Pb(II) adsorption using CFA-Dzt was 5. The adsorption kinetics of Pb(II) ions followed the pseudo-second-order kinetic model, with an adsorption activation energy of 27.280 kJ mol−1. The Langmuir isotherm model best described the adsorption behavior, with a maximum adsorption capacity of 34.13 mg g−1. Thermodynamic analysis revealed Gibbs free energy changes (ΔG°) of 24.630, 25.850, 26.810, and 28.550 kJ mol−1 at 293, 303, 313, and 323 K, respectively. The enthalpy change (ΔH°) of the adsorption at this temperature range was +12.770 kJ mol−1, indicating that Pb(II) ion adsorption on the adsorbent is an endothermic process, and its entropy change (ΔS°) was +127.290 J mol−1, suggesting that the adsorption of Pb(II) ion on CFA-Dzt is dominantly driven by the entropic factor.

Title

Found 6 Documents
Search

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Title Search

Found 6 Documents Search

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Title

Found 6 Documents
Search